A new treatment based on combining two drugs—nivolumab and ipilimumab—may represent a milestone in how we treat skin cancer patients. More than half of these patients can now survive the condition (considered untreatable just a decade ago) thanks to a study led by the...
TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.
159 WEST BROADWAY SUITE 200 SALT LAKE CITY, UT 84101
Pin It on Pinterest